Navigation Links
Human Genome Sciences Completes Enrollment in Randomized Phase 2 Trial of HGS-ETR1 in Non-Small Cell Lung Cancer
Date:8/22/2008

inical data suggests that combining HGS-ETR1 with chemotherapy agents could be an effective approach to the treatment of a number of malignancies, including non-small cell lung cancer," said Gilles Gallant, B. Pharm., Ph.D., Vice President, Clinical Research - Oncology, HGS. "HGS-ETR1 is the most advanced of any product in development that targets the TRAIL apoptotic pathway. The NSCLC study is one of three ongoing HGS trials designed to evaluate combinations of HGS-ETR1 with chemotherapeutic agents for the treatment of specific cancers."

About the HGS-ETR1 Proof-of-Concept Trials

The HGS-ETR1 proof-of-concept phase includes three randomized trials to evaluate its potential in combination with chemotherapy for the treatment of specific cancers:

-- Randomization and initial dosing of patients in the NSCLC study have now been completed.

-- In July 2008, HGS initiated dosing in the safety lead-in to a randomized Phase 2 trial of HGS-ETR1 in combination with Nexavar (sorafenib) in patients with advanced hepatocellular cancer, which accounts for 80-90% of all liver cancers.

-- The Company expects to have initial data available in the third quarter of 2008 from a randomized Phase 2 trial of HGS-ETR1 in combination with Velcade (bortezomib) in advanced multiple myeloma. Patients in the multiple myeloma study will continue on treatment until the progression of disease.

These three trials, taken together, will support a decision on whether to advance HGS-ETR1 to Phase 3 development. It also is possible that a sufficiently positive result from any one of the trials could lead to a Phase 3 decision for that specific indication.

About Non-Small Cell Lung Cancer

Non-small cell lung cancer accounts for approximately 75-80% of all lung cancers. It is estimated that more than 170,000 new cases and more than 160,000 deaths occur annually in the United States alone. It is currently the leading cause of cancer death in the U.S. i
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Boston University and The Center for Human Genetics, Inc. Announce Change in Testing Services
2. ViaViente Demonstrates Cardiovascular Benefits in New Human Trial
3. Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer
4. ProteoTechs Exebryl-1(R) Enters Human Clinical Trials for the Treatment of Alzheimers Disease
5. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105
6. deCODE and SGENE Consortium Discover Deletions in the Human Genome Linked to Risk of Schizophrenia
7. New Research on Pre-Eclampsia in Mice May Have Important Implications for Humans
8. Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine"
9. Vical Announces Breakthrough for Pandemic Influenza DNA Vaccines With Preliminary Human Data
10. Insmed Announces First Human Bioequivalence Data for a Follow-on Biologic by a U.S. Company
11. IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following June Meeting of European Committee for Medicinal Products for Human Use (CHMP)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... , May 4, 2015  The board of directors ... declared a dividend for the second quarter of 2015 of ... The dividend is payable June 10, 2015, to shareholders of ... About Eli Lilly and Company Lilly is a global ... better for people around the world. We were founded more ...
(Date:5/4/2015)... and TORONTO , May 4, 2015 ... today announced that it intends to dividend to its ... completion of a definitive licensing agreement to license its ... www.smoofi.com ) (OTCQB:SMFI). As announced on April ... intent in respect of the licensing of its RapidMist™ ...
(Date:5/4/2015)... May 4, 2015 PharmaEngine, Inc. (TWO:4162) ... Inc. (NASDAQ: MACK ) with its sublicensing ... jointly announced that Baxter has submitted a marketing ... (EMA) for MM-398 (irinotecan liposome injection), also known ... the pancreas who have been previously treated with ...
Breaking Medicine Technology:Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 2Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 3Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 4Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 5PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 2PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 3
(Date:5/4/2015)... New Jersey (PRWEB) May 04, 2015 Parlin ... to give a chance to more youths to participate and ... encourage youths in her area to do good deeds and ... Dr.Blagoev intends to empower their minds and teach them to ... contest is accessible to any youth 18 years of age ...
(Date:5/4/2015)... May 05, 2015 The ... Irene Taylor , Volunteer Executive Director of ... 2015-2016 inductee into its VIP Woman of the ... distinction for leadership in business. NAPW is the ... boasting more than 700,000 members and over 200 ...
(Date:5/4/2015)... (PRWEB) May 05, 2015 The ... Patti Hommes as a 2015-2016 inductee into its ... with this prestigious distinction for leadership in business. NAPW ... women, boasting more than 700,000 members and over 200 ... with this important honor,” says NAPW President Star Jones. ...
(Date:5/4/2015)... 2015 The National Association of ... as a 2015-2016 inductee into the NAPW VIP ... this prestigious distinction for leadership in business. NAPW is ... boasting more than 700,000 members and over 200 operating ... this important honor," said NAPW President Star Jones. "Her ...
(Date:5/4/2015)... May 05, 2015 The National ... Weis as a 2015-2016 inductee into its VIP ... this prestigious distinction for leadership in healthcare. NAPW is ... boasting more than 700,000 members and over 200 operating ... this important honor,” says NAPW President Star Jones. “Her ...
Breaking Medicine News(10 mins):Health News:10 More Days To Enter Good Deed Contest 2Health News:National Association of Professional Women Inducts Irene Taylor into its 2015-2016 VIP Woman of the Year Circle 2Health News:NAPW Inducts Patti Hommes, Director of Advancement Services, Springside Chestnut Hill Academy, a 2015-2016 Professional Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Gloria Betancourt, Receptionist at Consulate Health Care, into its 2015-2016 VIP Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Shirley Weis, President at Weis Associates, LLC, into its 2015-2016 VIP Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Shirley Weis, President at Weis Associates, LLC, into its 2015-2016 VIP Woman of the Year Circle 3
... researchers older people have a less chance of surviving lung ... in time. On an average older people are more susceptible ... a ventilator.// What's not been clear is whether they do ... new study suggests that age is indeed a factor in ...
... of serotonin-raising drugs like antidepressants and slimming pills in ... of durgs is by increasing the levels of serotonin, ... body.// Examples include diet pills, anti-migraine drugs and some ... Health welfare hospital, warn of the potential dangers of ...
... patients on long-term non-steroidal anti-inflammatory drug (NSAID) treatment ... can substantially reduce the risk of ulcer formation.// ... cent of H.pylori infections and reduced the six-month ... the control group to 12 per cent in ...
... women whose jobs require too much exposure to solvents ... have chilren with defective eyesight. Head researcher Dr. Gideon ... of Occupational health. ,They found that poor ... mothers were frequently exposed to organic solvents at work ...
... School researchers have discovered nearly all the genes responsible ... blinding diseases.Macular degeneration affects 20 per cent of people ... photoreceptor genes expressed int he retinal cells, which was ... for preserving and restoring the vision of those affected.// ...
... People who suffer from asthma, particularly women, may have ... period of 30 years, researchers studied almost 100,000 patients ... of the patients showed any signs of cancer at ... second year after asthma diagnosis until the last day ...
Cached Medicine News:Health News:Genes for Vision discovered 2
... System™ expands hospital-grade monitoring capabilities into the ... and disease state management. The system ... a full range of clinical applications, from ... hospital, to periodic monitoring of patients outside ...
Generra Focus 5 is a basic vital sign monitor. , ,Adult, pediatric, and neonatal. , ,Providing high quality, affordable products for efficiency in patient care....
... Acuity Central Monitoring Station provides alarm ... to 60 patients from a single ... simple point and click actions with ... clinician can initiate or change monitoring ...
... Central Monitoring Station allows emergency caregivers to ... and where it's needed. Central Station monitoring ... to emergency situations to increase the level ... ,Used in conjunction with Welch Allyn's ...
Medicine Products: